

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**REGENTS OF THE UNIVERSITY OF CALIFORNIA DBA RONALD
REAGAN UCLA PHARMACY,
JOHNESE SPISSO, ADMINISTRATOR
Permit No. PHE 48971,**

and

**HEIDI W. HENEN
Pharmacist License No. RPH 60494,**

Respondents.

Agency Case No. 7390

OAH NO. 2023070837

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Reapproval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on August 1, 2024.

It is so ORDERED on July 2, 2024.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is fluid and cursive, with the first name "Seung" and last name "Oh" clearly visible.

Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 LESLIE A. WALDEN
Deputy Attorney General
4 State Bar No. 196882
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6293
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

13 **REGENTS OF THE UNIVERSITY OF**
14 **CALIFORNIA DBA RONALD REAGAN**
15 **UCLA PHARMACY**
16 **Johnese Spisso, Administrator**
17 **757 Westwood Plaza, Ste. B140**
18 **Los Angeles, CA 90095**
19 **Permit No. PHE 48971,**

20 **and**

21 **HEIDI W. HENEN**
22 **5220 Lindley Ave, #1**
23 **Encino, CA 91316**
24 **Pharmacist License No. RPH 60494**

25 Respondents.

Case No. 7390

OAH No. 2023070837

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER FOR PUBLIC
REPROVAL AS TO REGENTS OF THE
UNIVERSITY OF CALIFORNIA DBA
RONALD REAGAN UCLA PHARMACY**

[Bus. & Prof. Code § 495]

26 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
27 entitled proceedings that the following matters are true:

28 **PARTIES**

1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy.
She brought this action solely in her official capacity and is represented in this matter by Rob

1 Bonta, Attorney General of the State of California, by Leslie A. Walden, Deputy Attorney
2 General.

3 2. Respondent Regents of the University of California dba Ronald Reagan UCLA
4 Pharmacy (Respondent) is represented in this proceeding by attorney Natalia Mazina, whose
5 address is: Mazina Law, 100 Pine Street, Suite 1250, San Francisco, CA 94111-5235.

6 **JURISDICTION**

7 3. On or about February 1, 2008, the Board issued Permit No. PHE 48971 to
8 Respondent. The Permit was in full force and effect at all times relevant to the charges brought in
9 Accusation No. 7390 and will expire on November 1, 2024, unless renewed.

10 4. Accusation No. 7390 was filed before the Board of Pharmacy (Board), Department of
11 Consumer Affairs and is currently pending against Respondent. The Accusation and all other
12 statutorily required documents were properly served on Respondent on May 17, 2023.
13 Respondent timely filed its Notice of Defense contesting the Accusation. A copy of Accusation
14 No. 7390 is attached as exhibit A and incorporated herein by reference.

15 **ADVISEMENT AND WAIVERS**

16 5. Respondent has carefully read, fully discussed with counsel, and understands the
17 charges and allegations in Accusation No. 7390. Respondent has also carefully read, fully
18 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
19 Order for Public Reprimand as to Respondent Regents of the University of California dba Ronald
20 Reagan UCLA Pharmacy.

21 6. Respondent is fully aware of its legal rights in this matter, including the right to a
22 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
23 the witnesses against them; the right to present evidence and to testify on its own behalf; the right
24 to the issuance of subpoenas to compel the attendance of witnesses and the production of
25 documents; the right to reconsideration and court review of an adverse decision; and all other
26 rights accorded by the California Administrative Procedure Act and other applicable laws.

27 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
28 every right set forth above.

1 **CULPABILITY**

2 8. Respondent understands and agrees that the charges and allegations in Accusation
3 No. 7390, if proven at a hearing, constitute cause for imposing discipline upon its Pharmacy
4 Permit

5 9. For the purpose of resolving the Accusation without the expense and uncertainty of
6 further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual
7 basis for the charges in the Accusation, and that Respondent hereby gives up its right to contest
8 those charges.

9 10. Respondent agrees that its Pharmacy Permit is subject to discipline and they agree to
10 be bound by the Disciplinary Order below.

11 **CONTINGENCY**

12 11. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent
13 understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may
14 communicate directly with the Board regarding this stipulation and settlement, without notice to
15 or participation by Respondent or its counsel. By signing the stipulation, Respondent understands
16 and agrees that they may not withdraw its agreement or seek to rescind the stipulation prior to the
17 time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its
18 Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Repeval as to
19 Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy shall be
20 of no force or effect, except for this paragraph, it shall be inadmissible in any legal action
21 between the parties, and the Board shall not be disqualified from further action by having
22 considered this matter.

23 12. The parties understand and agree that Portable Document Format (PDF) and facsimile
24 copies of this Stipulated Settlement and Disciplinary Order for Public Repeval as to Respondent
25 Regents of the University of California dba Ronald Reagan UCLA Pharmacy, including PDF and
26 facsimile signatures thereto, shall have the same force and effect as the originals.

27 13. This Stipulated Settlement and Disciplinary Order for Public Repeval as to
28 Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy is

1 intended by the parties to be an integrated writing representing the complete, final, and exclusive
2 embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements,
3 understandings, discussions, negotiations, and commitments (written or oral). This Stipulated
4 Settlement and Disciplinary Order for Public Reapproval as to Respondent Regents of the
5 University of California dba Ronald Reagan UCLA Pharmacy may not be altered, amended,
6 modified, supplemented, or otherwise changed except by a writing executed by an authorized
7 representative of each of the parties.

8 14. In consideration of the foregoing admissions and stipulations, the parties agree that
9 the Board may, without further notice or formal proceeding, issue and enter the following
10 Disciplinary Order:

11 **DISCIPLINARY ORDER**

12 IT IS HEREBY ORDERED that Pharmacy Permit No. PHE 48971 issued to Respondent
13 Regents of the University of California dba Ronald Reagan UCLA Pharmacy shall be publicly
14 reapproved by the Board of Pharmacy under Business and Professions Code section 495 in
15 resolution of Accusation No. 7390, attached as exhibit A.

16 **Cost Recovery.** No later than one (1) year from the effective date of the Decision,
17 Respondent shall pay \$16,512 to the Board for its costs associated with the investigation and
18 enforcement of this matter pursuant to Business and Professions Code Section 125.3. If
19 Respondent fails to pay the Board costs as ordered, Respondent shall not be allowed to renew
20 their Permit until Respondent pays costs in full. In addition, the Board may enforce this order for
21 payment of its costs in any appropriate court, in addition to any other rights the Board may have.

22 **Full Compliance.** As a resolution of the charges in Accusation No. 7390, this stipulated
23 settlement is contingent upon Respondent's full compliance with all conditions of this Order. If
24 Respondent fails to satisfy any of these conditions, such failure to comply constitutes cause for
25 discipline, including outright revocation, of Respondent's Pharmacy Permit No. PHE 48971.

1
2 DATED: _____

3 REGENTS OF THE UNIVERSITY OF
4 CALIFORNIA DBA RONALD REAGAN UCLA
5 PHARMACY
6 JOHNESE SPISSO, ADMINISTRATOR
7 *Respondent*

8 I have read and fully discussed with Respondent Regents of the University of California
9 dba Ronald Reagan UCLA Pharmacy the terms and conditions and other matters contained in the
10 above Stipulated Settlement and Disciplinary Order for Public Reproval. I approve its form and
11 content.

12 DATED: _____

13 NATALIA MAZINA
14 *Attorney for Respondent*
15 REGENTS OF THE UNIVERSITY OF
16 CALIFORNIA DBA RONALD REAGAN UCLA
17 PHARMACY


18 ///

19 ///

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order for Public Reproval as to Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy and have fully discussed it with my attorney, Natalia Mazina. I understand the stipulation and the effect it will have on my Permit. I enter into this Stipulated Settlement and Disciplinary Order for Public Reproval voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.


DATED: 05/03/2024



REGENT UNIVERSITY OF
CALIFORNIA DBA RONALD REAGAN UCLA
PHARMACY
JOHNESE SPISSO, ADMINISTRATOR
Respondent

I have read and fully discussed with Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order for Public Reproval. I approve its form and content.

DATED: 05/03/2024



NATALIA MAZINA
Attorney for Respondent
REGENTS OF THE UNIVERSITY OF
CALIFORNIA DBA RONALD REAGAN UCLA
PHARMACY

////

////

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval as to Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED: _____

Respectfully submitted,

ROB BONTA
Attorney General of California
THOMAS L. RINALDI
Supervising Deputy Attorney General

LESLIE A. WALDEN
Deputy Attorney General
Attorneys for Complainant

LA2022603756
66754032.docx

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Reapproval as to Respondent Regents of the University of California dba Ronald Reagan UCLA Pharmacy is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED: 5/3/24

Respectfully submitted,

ROB BONTA
Attorney General of California
THOMAS L. RINALDI
Supervising Deputy Attorney General

Leslie Walden

LESLIE A. WALDEN
Deputy Attorney General
Attorneys for Complainant

LA2022603756
66754032.docx

Exhibit A

Accusation No. 7390

1 ROB BONTA
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 LESLIE A. WALDEN
Deputy Attorney General
4 State Bar No. 196882
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6293
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7390

13 **REGENTS OF THE UNIVERSITY OF**
14 **CALIFORNIA DBA RONALD REAGAN**
15 **UCLA PHARMACY**
16 **Johnese Spisso, Administrator**
17 **757 Westwood Plaza, Ste. B140**
18 **Los Angeles, CA 90095**

ACCUSATION

19 **Permit No. PHE 48971,**

20 **and**

21 **HEIDI W. HENEN**
22 **5220 Lindley Ave, #1**
23 **Encino, CA 91316**

24 **Pharmacist License No. RPH 60494**

25 Respondents.
26
27
28

1 **PARTIES**

2 1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
3 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

4 2. On or about February 1, 2008, the Board of Pharmacy issued Permit Number PHE
5 48971 to Regents of the University of California dba Ronald Reagan UCLA Pharmacy, Johnese
6 Spisso Administrator (UCLA). The Permit was in full force and effect at all times relevant to the
7 charges brought herein and will expire on November 1, 2023, unless renewed.

8 3. On or about November 28, 2007, the Board of Pharmacy issued Pharmacist License
9 Number RPH 60494 to Heidi W. Henen (Henen). The Pharmacist License was in full force and
10 effect at all times relevant to the charges brought herein and will expire on May 31, 2023, unless
11 renewed. Henen was the Pharmacist in Charge at UCLA at all times relevant to the charges
12 brought herein

13 **JURISDICTION**

14 4. This Accusation is brought before the Board of Pharmacy (Board), under the
15 authority of the following laws. All section references are to the Business and Professions Code
16 (Code) unless otherwise indicated.

17 5. Code section 4011 provides that the Board shall administer and enforce both the
18 Pharmacy Law (Bus. & Prof. Code, § 4000 et seq.) and the Uniform Controlled Substances Act
19 (Health & Safety Code, § 11000 et seq.).

20 6. Code section 4300, subdivision (a) provides that every license issued by the Board
21 may be suspended or revoked.

22 7. Code section 4300.1 states:

23 The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation
24 of law or by order or decision of the board or a court of law, the placement of a license on a
25 retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of
26 jurisdiction to commence or proceed with any investigation of, or action or disciplinary
27 proceeding against, the licensee or to render a decision suspending or revoking the license.

28 ///

1
2 8. Code section 4307, subdivision (a) states:

3 Any person who has been denied a license or whose license has been revoked or is under
4 suspension, or who has failed to renew his or her license while it was under suspension, or who
5 has been a manager, administrator, owner member, officer, director, associate, or partner of any
6 partnership, corporation, firm, or association whose application for a license has been denied or
7 revoked, is under suspension or has been placed on probation, and while acting as the manger,
8 administrator, owner, member, officer, director, associate, or partner had knowledge or
9 knowingly participated in any conduct for which the license was denied, revoked, suspended, or
10 placed on probation, shall be prohibited from serving as a manger, administrator, owner, member,
11 officer, director, associate, or partner of a licensee as follows:

12 (1) Where a probationary license is issued or where an existing license is placed on
13 probation, this prohibition shall remain in effect for a period not to exceed five years.

14 (2) Where the license is denied or revoked, the prohibition shall continue until the license is
15 issued or reinstated.

16 9. Code section 4342, subdivision (a) states:

17 The board may institute any action or actions as may be provided by law and that, in its
18 discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do not
19 conform to the standard and tests as to quality and strength, provided in the latest edition of the
20 United States Pharmacopoeia or the National Formulary, or that violate any provision of the
21 Sherman Food, Drug, and Cosmetic Law (Part 5 (commencing with section 109875) of Division
22 104 of the Health & Safety Code).

23 **STATUTORY PROVISIONS**

24 10. Code section 4023.5 states:

25 For the purposes of this chapter, “direct supervision and control” means that a pharmacist is
26 on the premises at all times and is fully aware of all activities performed by either a pharmacy
27 technician or intern pharmacist.

28 ///

11. Section 4022 of the Code states:

"Dangerous drug" or "dangerous device" means any drug or device unsafe for self-use in humans or animals, and includes the following:

(a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without prescription," "Rx only," or words of similar import.

(b) Any device that bears the statement: "Caution: federal law restricts this device to sale by or on the order of a ____" "Rx only," or words of similar import, the blank to be filled in with the designation of the practitioner licensed to use or order use of the device.

(c) Any other drug or device that by federal or state law can be lawfully dispensed only on prescription or furnished pursuant to Section 4006.

12. Code section 4113, subdivision (c) states:

The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

13. Code section 4115, subdivision (a) states:

A pharmacy technician may perform packaging, manipulative, repetitive, or other nondiscretionary tasks only while assisting, and while under the direct supervision and control of, a pharmacist. The pharmacist shall be responsible for the duties performed under his or her supervision by a technician.

14. Code section 4116, subdivision (a) states:

No person other than a pharmacist, an intern pharmacist, an authorized officer of the law, or a person authorized to prescribe shall be permitted in that area, place, or premises described in the license issued by the board wherein controlled substances or dangerous drugs or dangerous devices are stored, possessed, prepared, manufactured, derived, compounded, dispensed, or re-packaged. However, a pharmacist shall be responsible for any individual who enters the pharmacy for the purposes of receiving consultation from the pharmacist or performing clerical, inventory control, housekeeping, delivery, maintenance, or similar functions relating to the pharmacy if the pharmacist remains present in the pharmacy during all times as the authorized individual is present.

1 15. Section 4301 of the Code states in pertinent part:

2 The board shall take action against any holder of a license who is guilty of
3 unprofessional conduct or whose license has been issued by mistake. Unprofessional
4 conduct shall include, but is not limited to, any of the following:

5 ...

6 (j) The violation of any of the statutes of this state, or any other state, or of the United
7 States regulating controlled substances and dangerous drugs.

8 ...

9 (o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting
10 the violation of or conspiring to violate any provision or term of this chapter or of the applicable
11 federal and state laws and regulations governing pharmacy, including regulations established by
12 the board or any other state or federal regulatory agency....

13 16. Section 4059.5 of the Code states:

14 (a) Except as otherwise provided in this chapter, dangerous drugs or dangerous devices
15 may only be ordered by an entity licensed by the board and shall be delivered to the licensed
16 premises and signed for and received by a pharmacist. Where a licensee is permitted to operate
17 through a designated representative, or in the case of a reverse distributor a designated
18 representative-reverse distributor, that individual shall sign for and receive the delivery.

19 **REGULATORY PROVISIONS**

20 17. California Code of Regulations, title 16, section 1714, subdivision (d) states:

21 Each pharmacist while on duty shall be responsible for the security of the prescription
22 department, including provisions for effective control against theft or diversion of dangerous
23 drugs and devices, and records for such drugs and devices. Possession of a key to the pharmacy
24 where dangerous drugs and controlled substances are stored shall be restricted to a pharmacist.

25 **COST RECOVERY**

26 18. Section 125.3 of the Code states, in pertinent part, that the Board may request the
27 administrative law judge to direct a licensee found to have committed a violation or violations of
28

the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

DRUG DEFINITIONS

19. Gengraf, a brand name for Cyclosporine, is a dangerous drug pursuant to Business & Professions Code section 4022. Gengraf is used to treat organ rejection.

20. Coly-Mycin, a brand name for Cholistimethate, is a dangerous drug pursuant to Business & Professions Code section 4022. Coly-Mycin is an antibiotic.

21. Leukine, a brand name for Sargramostim, is a dangerous drug pursuant to Business & Professions Code section 4022. Leukine is used to treat Leukemia.

22. Klonopin, a brand name for Clonazepam, is Schedule IV controlled substance as designated by Health and Safety Code section 11057(d)(7), and is a dangerous drug pursuant to Business & Professions Code section 4022. Klonopin is used to treat panic disorders and seizures.

23. Opium Tincture is Schedule II controlled substance as designated by Health and Safety Code section 11055(b)(1)(F), and is a dangerous drug pursuant to Business & Professions Code section 4022. Opium Tincture is used to treat diarrhea.

24. Duragesic, a brand name for Fentanyl, is Schedule II controlled substance as designated by Health and Safety Code section 11055(c)(8), and is a dangerous drug pursuant to Business & Professions Code section 4022. Duragesic is used to treat pain.

25. Vyvanse, a brand name for Lisdexamfetamine Dimesylate, is Schedule II controlled substance as designated by Health and Safety Code section 11055(f)(1), and is a dangerous drug pursuant to Business & Professions Code section 4022. Vyvanse is used to treat Attention Deficit Hyperactivity Disorder.

26. Dilaudid, a brand name for Hydromorphone, is Schedule II controlled substance as designated by Health and Safety Code section 11055(b)(1)(J), and is a dangerous drug pursuant to Business & Professions Code section 4022. Dilaudid is used to treat pain.

1 **FACTUAL ALLEGATIONS**

2 27. On or about December 2, 2021 and December 14, 2021, the Board received
3 anonymous complaints from employees at UCLA alleging that Henen, the Pharmacists in charge
4 at UCLA, allowed a non-pharmacist to open the pharmacy and sign for the delivery of controlled
5 substances. The Board commenced an investigation, which revealed that from on or about May
6 1, 2019 through May 1, 2020, UCLA and Henen allowed non-pharmacists to sign for the delivery
7 of approximately 9005 containers of non-controlled prescription medications, 415 containers of
8 Schedule III-V prescription medications, and 421 containers of Schedule II prescription
9 medications from Amerisource Wholesaler. The investigation revealed that different pharmacy
10 technicians signed for and received approximately 270 delivery manifests containing dangerous
11 drugs and devices, including but not limited to Gengraf, Coly-Mycin. Leukine, Klonopin, Opium
12 Tincture, Duragesic, Vyvanse and Dilaudid.

13 **FIRST CAUSE FOR DISCIPLINE**

14 (Allowing Non-Pharmacists to Sign For and Receive Dangerous Drugs and Controlled
15 Substances)

16 28. Respondents UCLA and Henen are subject to disciplinary action under Code sections
17 4301 subdivisions (j) and (o), and 4059.5 in that they allowed non-pharmacists to sign for and
18 receive controlled substances and dangerous drugs from on or about May 1, 2019 through May 1,
19 2020 at UCLA. The circumstances surrounding this violation are set forth in paragraph 27 above,
20 and are incorporated herein as though set forth in full.

21 **SECOND CAUSE FOR DISCIPLINE**

22 (Failure to Maintain the Security of the Prescription Department at UCLA)

23 29. Respondent Henen is subject to disciplinary action under Business and Professions
24 Code section 4301, subdivision (o) in conjunction with title 16, of the California Code of
25 Regulations, section 1714, subdivision (d) for failing to ensure the security of the prescription
26 department at UCLA. The circumstances surrounding this violation are set forth in paragraph 27
27 above, and are incorporated herein as though set forth in full.

1 **DISCIPLINE CONSIDERATIONS**

2 30. To determine the degree of discipline, if any, to be imposed on Respondent UCLA,
3 Complainant alleges that on or about April 28, 2020, the Board issued Letter of Admonishment
4 Number to CI 2018 84033 to UCLA under Business and Professions Code sections 4315 and
5 1707.5 subdivision (a)(1) for failure to print the drug manufacturer on prescription labels.

6 **OTHER MATTERS**

7 31. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number
8 PHE 48971 issued to Regents of the University of California dba Ronald Reagan UCLA
9 Pharmacy, it shall be prohibited from serving as a manager, administrator, owner, member,
10 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number
11 PHE 48971 is placed on probation or until Pharmacy Permit Number PHE 48971 is reinstated if it
12 is revoked.

13 32. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number
14 PHE 48971 issued to Regents of the University of California dba Ronald Reagan UCLA
15 Pharmacy, while Johnese Spisso was the Administrator, and had knowledge of or knowingly
16 participated in any conduct for which the licensee was disciplined, Spisso shall be prohibited
17 from serving as a manager, administrator, owner, member, officer, director, associate, or partner
18 of a licensee for five years if Pharmacy Permit Number PHE 48971 is placed on probation or until
19 Pharmacy Permit Number PHE 48971 is reinstated if it is revoked.

20 33. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License
21 Number RPH 60494 issue to Heidi W. Henen, Henen shall be prohibited from serving as a
22 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for
23 five years if Pharmacist License Number RPH 60494 is placed on probation or until Pharmacist
24 License Number RPH 60494 is reinstated if it is revoked.

25 **PRAYER**

26 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
27 and that following the hearing, the Board of Pharmacy issue a decision:
28

- 1 1. Revoking or suspending Permit Number PHE 48971, issued to Regents of the
2 University of California dba Ronald Reagan UCLA Pharmacy;
- 3 2. Revoking or suspending Pharmacist License Number RPH 60494, issued to Heidi W.
4 Henen;
- 5 3. Prohibiting Johnese Spisso from serving as a manager, administrator, owner, member,
6 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number
7 PHE 48971 is placed on probation or until Pharmacy Permit Number PHE 48971 is reinstated if
8 Pharmacy Permit Number PHE 48971 issued to Regents of the University of California dba
9 Ronald Reagan UCLA Pharmacy is revoked;
- 10 4. Prohibiting Regents of the University of California dba Ronald Reagan UCLA
11 Pharmacy from serving as a manager, administrator, owner, member, officer, director, associate,
12 or partner of a licensee for five years if Pharmacy Permit Number PHE 48971 is placed on
13 probation or until Pharmacy Permit Number PHE 48971 is reinstated if Pharmacy Permit Number
14 PHE 48971 issued to Regents of the University of California dba Ronald Reagan UCLA
15 Pharmacy is revoked;
- 16 5. Prohibiting Heidi W. Henen from serving as a manager, administrator, owner,
17 member, officer, director, associate, or partner of a licensee for five years if Pharmacist License
18 Number RPH 60494 is placed on probation or until Pharmacist License Number RPH 60494 is
19 reinstated if Pharmacist License Number RPH 60494 issued to Heidi W. Henen is revoked;
- 20 3. Ordering Ronald Reagan UCLA Outpatient Pharmacy and Heidi W. Henen to pay the
21 Board of Pharmacy the reasonable costs of the investigation and enforcement of this case,
22 pursuant to Business and Professions Code section 125.3; and,
- 23 4. Taking such other and further action as deemed necessary and proper.

24 DATED: 3/6/2023

Sodergren,
Anne@DCA

Digitally signed by Sodergren, Anne@DCA
Date: 2023.03.06 21:27:56 -08'00'

ANNE SODERGREN
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

25
26
27
28 LA2022603756
65710707.docx